HPV Infections

22 registered clinical trials studyying HPV Infections — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer NCT07281599	Qurasense	N/A
Not Yet Recruiting	Tolerance and Effectiveness of C14 on HPV Infection NCT06672653	MGB Pharma	Phase 1 / Phase 2
Completed	Cervical Cancer Screening of Postmenopausal Women in Low- and Middle-income Countries Using HPV Self-sampling NCT07244315	University Hospital, Geneva	—
Completed	A Phase 1 Study of PV-001 9-valent Human Papillomavirus(HPV) Vaccine NCT07081334	POSVAX	Phase 1
Recruiting	Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine NCT05371353	Shanghai Bovax Biotechnology Co., Ltd.	—
Recruiting	Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years NCT05027776	Shanghai Bovax Biotechnology Co., Ltd.	Phase 3
Recruiting	Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Year NCT04895020	Shanghai Bovax Biotechnology Co., Ltd.	Phase 3
Completed	Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females NCT05372016	Shanghai Bovax Biotechnology Co., Ltd.	Phase 3
Completed	A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine NCT03900572	Shanghai Zerun Biotechnology Co.,Ltd	Phase 1
Completed	A Phase I Study of Quadrivalent HPV Recombinant Vaccine NCT03085381	Shanghai Bovax Biotechnology Co., Ltd.	Phase 1
Unknown	Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China NCT01021904	Chinese Academy of Medical Sciences	Phase 4
Completed	Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191 NCT01086709	National Cancer Institute (NCI)	—
Completed	Human Papillomavirus (HPV) Genotypes in Genital Warts in Colombian Population NCT00847340	La Fundacion para la Investigacion y el Desarrollo	—
Withdrawn	Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034) NCT00733122	Merck Sharp & Dohme LLC	Phase 3
Completed	Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls NCT00956553	Public Health England	Phase 4
Completed	A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolesce NCT00943722	Merck Sharp & Dohme LLC	Phase 3
Completed	Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041) NCT00834106	Merck Sharp & Dohme LLC	Phase 3
Completed	Significance of the High-risk Hpv Viral Load NCT00682812	Assistance Publique Hopitaux De Marseille	N/A
Completed	An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035) NCT00635830	Merck Sharp & Dohme LLC	Phase 1
Completed	A Study to Identify Markers in Blood and Tissue of HPV Clearance NCT00711815	University of Alabama at Birmingham	—
Completed	V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028) NCT00411749	Merck Sharp & Dohme LLC	Phase 2
Completed	V501 Efficacy Study in Women Aged 18 to 26 (V501-027) NCT00378560	Merck Sharp & Dohme LLC	Phase 2